DepoMed, Inc. (NASDAQ: DEPO) reported Q2 EPS of ($0.01), $0.07 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $67.7 million versus the consensus estimate of $38.03 million.

For earnings history and earnings-related data on DepoMed, Inc. (DEPO) click here.